US FDA’s Potential Class Of 2021 By The Numbers
Our infographic breaks down the bumper crop.
You may also be interested in...
Dermatology, chronic kidney disease and liver disease therapies stand out in a crowd of user fee goals that is actually bigger than at the same point in 2020.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
User fee goal dates are coming up in October for more than 15 applications, according to the Pink Sheet’s US FDA Performance Tracker.